Altered Calcium Handling Is Critically Involved in the Cardiotoxic Effects of Chronic β-Adrenergic Stimulation

Circulation

Volumn 109, Issue 9, 2004, Pages 1154-1160

  Engelhardt, Stefan ^a,d   Hein, Lutz ^a   Dyachenkow, Vitaly ^b   Kranias, Evangelia G ^c   Isenberg, Gerrit ^b   Lohse, Martin J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Calcium; Heart failure; Hypertrophy; Sarcoplasmic reticulum

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CALCIUM; PHOSPHOLAMBAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLE; DNA MODIFICATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE FIBROSIS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SURVIVAL; TRANSGENE; WILD TYPE;

ANIMALS; CALCIUM; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; FIBROSIS; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIUM; PULMONARY EDEMA; RECEPTORS, ADRENERGIC, BETA-1; RNA, MESSENGER; SURVIVAL ANALYSIS; VENTRICULAR FUNCTION, LEFT;

EID: 1542409908     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000117254.68497.39     Document Type: Article

References (30)

1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
2. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart failure? Circ Res. 2003;93:896-906.
3. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
4. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-7064.
5. 1-adrenergic receptor. FASEB J. 2001;15:2718-2720.
6. 1-adrenergic receptor transgenic mice. Circ Res. 2002;90:814-819.
7. Isenberg G, Klockner U. Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium." Pflugers Arch. 1982;395:6-18.
8. 2+-release. J Physiol. 1994;480:411-421.
9. 2+-indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
10. Simmerman HK, Jones LR. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev. 1998;78:921-947.
11. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res. 1994;75:401-409.
12. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
13. 2+-handling in cardiac hypertrophy and heart failure. Cardiovasc Res. 1998;37:290-299.
14. 2+-handling in experimental pressure-overload hypertrophy in the ferret. Circ Res. 1985;57:836-843.
15. 2+-handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61:70-76.
16. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
17. 2+ homeostasis and cardiac contractility. J Mol Cell Cardiol. 2001;33:1053-1063.
18. del Monte F, Hajjar RJ. Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol. 2003;546:49-61.
19. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99:313-322.
20. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001;107:967-974.
21. Sato Y, Kiriazis H, Yatani A, et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem. 2001;276:9392-9399.
22. Delling U, Sussman MA, Molkentin JD. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med. 2000;6:942-943.
23. Song Q, Schmidt AG, Hahn HS, et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest. 2003;111:859-867.
24. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111:869-876.
25. Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-1413.
26. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002;109:1013-1020.
27. Factor SM, Cho SH, Scheuer J, et al. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J Am Coll Cardiol. 1988;12:1599-1604.
28. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000;6:1221-1227.
29. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
30. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110:479-488.